Press Releases Archives | Page 22 of 118

FREE organoid and organ-on-chip TRAINING and TICKETS at WORD+2025!

December 4, 2024 By Cade Hildreth, Founder & President Leave a Comment

We are excited to announce these latest organoid and organ-on-a-chip partnerships for training and publishing.

WORC.Community, the founders of WORD+2025, QMUL Centre for Predictive in vitro Models and the University of Bern are excited to announce a new Organoid and Organ-on-a-chip training partnership on day three of WORD+2025. The training is a series of interactive lectures in the main auditorium. You’ll learn about the latest techniques and key methods employed at both universities. In addition, there will also be demonstrations from key technologies used in their workflows. [Read more…]

Elevai Labs Releases Preliminary Positive Research on the Potential of Exosome Technology for Skin Health

December 2, 2024 By Cade Hildreth, Founder & President Leave a Comment

Preliminary data from the research study in partnership with Dalhousie University demonstrates that Elevai’s hUMSC derived exosomes (“ELEVAI exosomes™”) contain over 800 proteins that are associated with wound healing, immunomodulation and remodeling of the skin’s extracellular matrix (“ECM”).

Data implies ELEVAI exosomes™ may be a source for proteins that typically decrease with age, and can be important components that prevent skin thinning, loss of elasticity and wrinkle formation.

[Read more…]

Proudly Supporting Great Science and Women in STEM

December 1, 2024 By Cade Hildreth, Founder & President Leave a Comment

WORD+ 2025 is pleased to introduce its conference chairs and speakers.

FYI: In February 2025, 60% of session chairs and 54% of speakers will be leading scientists who are female. [Read more…]

Cellistic® Announces Successful Certification of its GMP Facility Dedicated to iPSC-Based Off-the-shelf Cell Therapy Manufacturing Solutions

November 22, 2024 By Cade Hildreth, Founder & President Leave a Comment

November 21, 2024, MONT-SAINT-GUIBERT, Belgium — Cellistic®, a pioneer in iPSC-based off-the-shelf cell therapy development and manufacturing, announces the successful audit and GMP certification of its first-of-its kind facility dedicated to manufacturing therapies based on induced pluripotent stem cells (iPSCs). This achievement signifies Cellistic’s quality and regulatory readiness, which is now certified by the Belgian Federal Agency for Medicines and Health Products (FAMHP), operating under European Medicines Agency (EMA) guidelines. [Read more…]

Autolus Latest Competitor in Global CAR-T Frenzy with FDA Approval of Aucatzyl

November 22, 2024 By Cade Hildreth, Founder & President Leave a Comment

On November 8, 2024, the U.S. FDA issued a historic approval of the seventh CAR-T cell therapy to be approved in the U.S. and the 11th CAR-T therapy to be approved globally. This approval was for Autolus Inc.’s Aucatzyl (obecabtagene autoleucel), a CD19-directed genetically modified autologous T cell immunotherapy, for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). Autolus is a U.K. biotech company that develops novel gene-modified T cell therapies for the treatment of cancer. [Read more…]